ABSTRACT

Introduction

Gastrointestinal cancers contribute to a significant number of cancer- associated mortality. The gastrointestinal tract harbors a multitude of microorganisms, known as the microbiota. Recently, the microbiota is considered to be an accessory organ resulting in several health benefits. The microbiota is involved in almost all aspects of an individual ranging from managing behavior to controlling metabolism, immune status and the response to a disease. Researchers are observing the modulation of microbiota in almost every disease, including cancer. Probiotics are microorganisms that can help to alter the host microbiota toward a healthy state thus providing benefits from many diseases including cancer.

Areas covered

We explored the current status of the use of probiotics in cancer patients. Although probiotic bacteria can provide significant benefits to individuals suffering from cancer, the number of cancer-specific clinical products containing probiotics is not comparable to research studies showing their benefits. The lack of available products is due to several factors including a lack of risk assessment data of beneficial probiotics in cancer patients.

Expert opinion

Laboratory investigations indicate a huge potential of probiotics for the prevention and management of gastrointestinal cancer, but more clinical studies are required to support their application in clinical settings.

中文翻译：

---

益生菌在胃肠道癌症预防和管理中的现状

摘要

介绍

胃肠癌导致大量癌症相关死亡。胃肠道含有大量微生物，称为微生物群。最近，微生物群被认为是具有多种健康益处的辅助器官。微生物群几乎涉及个人的所有方面，从管理行为到控制新陈代谢、免疫状态和对疾病的反应。研究人员正在观察几乎所有疾病（包括癌症）中微生物群的调节。益生菌是一种微生物，可以帮助将宿主微生物群转变为健康状态，从而从包括癌症在内的许多疾病中受益。

覆盖区域

我们探讨了益生菌在癌症患者中的使用现状。虽然益生菌可以为癌症患者提供显着的益处，但含有益生菌的癌症特异性临床产品的数量无法与显示其益处的研究相提并论。可用产品的缺乏是由于多种因素造成的，包括缺乏对癌症患者有益益生菌的风险评估数据。

专家意见

实验室研究表明益生菌在预防和管理胃肠道癌症方面具有巨大潜力，但需要更多的临床研究来支持它们在临床环境中的应用。